OEIC

True Potential Appoints Northern Trust for Asset Servicing Solutions

Retrieved on: 
Friday, January 19, 2024

Northern Trust (Nasdaq: NTRS) today announces it has been appointed to provide asset servicing solutions to True Potential, a United Kingdom (UK)-headquartered wealth management firm, supporting GBP26 billion (approx.

Key Points: 
  • Northern Trust (Nasdaq: NTRS) today announces it has been appointed to provide asset servicing solutions to True Potential, a United Kingdom (UK)-headquartered wealth management firm, supporting GBP26 billion (approx.
  • US$33bn) of its assets under management (source: True Potential, 17 January 2024).
  • Northern Trust is providing fund accounting, custody, depositary and transfer agency services to True Potential’s open-ended investment company (OEIC) UK-domiciled fund range.
  • Its investment products include the True Potential Wealth Strategy Funds – aimed at helping clients manage wealth in a simple solution – and True Potential Portfolios, a suite of diversified, discretionary-managed investment solutions.

Capital Group Selects SS&C to Provide Transfer Agency for U.K. Fund Launch

Retrieved on: 
Wednesday, January 25, 2023

WINDSOR, Conn., Jan. 25, 2023 /PRNewswire/ -- SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that Capital Group has appointed SS&C Global Investor and Distribution Solutions (GIDS) to provide transfer agency services for its recently launched UK OEIC, the Capital Group U.K. – Global High Income Opportunities Fund.

Key Points: 
  • WINDSOR, Conn., Jan. 25, 2023 /PRNewswire/ -- SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that Capital Group has appointed SS&C Global Investor and Distribution Solutions (GIDS) to provide transfer agency services for its recently launched UK OEIC, the Capital Group U.K. – Global High Income Opportunities Fund.
  • Capital Group is one of the world's largest and most experienced investment companies, with assets under management of over US$ 2.1 trillion.
  • SS&C GIDS is a transfer agent to Capital Group in the U.S .
  • "We are truly excited to collaborate with Capital Group on the launch of the new U.K. fund," said Spencer Baum, Head of Client Service and Relationship Management at SS&C GIDS.

Capital Group Selects SS&C to Provide Transfer Agency for U.K. Fund Launch

Retrieved on: 
Wednesday, January 25, 2023

WINDSOR, Conn., Jan. 25, 2023 /PRNewswire/ -- SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that Capital Group has appointed SS&C Global Investor and Distribution Solutions (GIDS) to provide transfer agency services for its recently launched UK OEIC, the Capital Group U.K. – Global High Income Opportunities Fund.

Key Points: 
  • WINDSOR, Conn., Jan. 25, 2023 /PRNewswire/ -- SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that Capital Group has appointed SS&C Global Investor and Distribution Solutions (GIDS) to provide transfer agency services for its recently launched UK OEIC, the Capital Group U.K. – Global High Income Opportunities Fund.
  • Capital Group is one of the world's largest and most experienced investment companies, with assets under management of over US$ 2.1 trillion.
  • SS&C GIDS is a transfer agent to Capital Group in the U.S .
  • "We are truly excited to collaborate with Capital Group on the launch of the new U.K. fund," said Spencer Baum, Head of Client Service and Relationship Management at SS&C GIDS.

Quilter Investors Extends Transfer Agent Relationship with SS&C

Retrieved on: 
Tuesday, January 17, 2023

WINDSOR, Conn., Jan. 17, 2023 /PRNewswire/ -- SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that Quilter Investors Limited, the fund management arm of Quilter Plc, has extended its long-term transfer agency relationship with SS&C Global Investor and Distribution Solutions (GIDS).

Key Points: 
  • WINDSOR, Conn., Jan. 17, 2023 /PRNewswire/ -- SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that Quilter Investors Limited, the fund management arm of Quilter Plc, has extended its long-term transfer agency relationship with SS&C Global Investor and Distribution Solutions (GIDS).
  • Quilter Investors specialises in the creation and management of multi-asset investment portfolios.
  • SS&C first started working with Quilter Investors in 2014.
  • We are committed to delivering industry-leading service levels to aid Quilter Investors in their retention and capture of new assets through multiple distribution channels."

Quilter Investors Extends Transfer Agent Relationship with SS&C

Retrieved on: 
Tuesday, January 17, 2023

WINDSOR, Conn., Jan. 17, 2023 /PRNewswire/ -- SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that Quilter Investors Limited, the fund management arm of Quilter Plc, has extended its long-term transfer agency relationship with SS&C Global Investor and Distribution Solutions (GIDS).

Key Points: 
  • WINDSOR, Conn., Jan. 17, 2023 /PRNewswire/ -- SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that Quilter Investors Limited, the fund management arm of Quilter Plc, has extended its long-term transfer agency relationship with SS&C Global Investor and Distribution Solutions (GIDS).
  • Quilter Investors specialises in the creation and management of multi-asset investment portfolios.
  • SS&C first started working with Quilter Investors in 2014.
  • We are committed to delivering industry-leading service levels to aid Quilter Investors in their retention and capture of new assets through multiple distribution channels."

NETRIS Pharma Doses First Patient in Phase 2 Study of NP137 for Checkpoint Inhibitor Resistance

Retrieved on: 
Tuesday, November 29, 2022

The enrollment of the first patient in ImmunoNET is a new clinical milestone for NETRIS Pharma.

Key Points: 
  • The enrollment of the first patient in ImmunoNET is a new clinical milestone for NETRIS Pharma.
  • Based on a unique mode of action of NP137 and biomarker studies conducted in Phase 1, we believe we can enlarge the fraction of responding patients and potentially prevent resistance, said Patrick Mehlen, CEO of NETRIS Pharma.
  • ImmunoNET has been specifically designed by clinicians to provide new solutions for patients suffering from resistance to immune-checkpoint inhibitors.
  • NETRIS Pharma, a clinical-stage company designs and develops anti-cancer therapeutic molecules, particularly monoclonal antibodies, to block the interaction between dependence receptors and their ligands.

Jupiter Asset Management Extends Relationship with SS&C

Retrieved on: 
Thursday, November 24, 2022

WINDSOR, Conn., Nov. 23, 2022 /PRNewswire/ -- SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that Jupiter Asset Management, an investment management group, has extended its transfer agency contract with SS&C. SS&C provides services to Jupiter's unit trusts and has now taken on Jupiter's OEIC fund range acquired in 2020 as part of the Merian acquisition. The entire range of funds administered by SS&C exceeds GBP28 billion.

Key Points: 
  • WINDSOR, Conn., Nov. 23, 2022 /PRNewswire/ -- SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that Jupiter Asset Management, an investment management group, has extended its transfer agency contract with SS&C.
  • Jupiter will also take advantage of SS&C's advanced data processing and analytics to gather insights into fund flow and client activity.
  • "We are pleased to extend our valued long-term relationship with Jupiter," said Nick Wright, General Manager, SS&C GIDS.
  • Jupiter Asset Managementis aU.K.fund management group, managing equity and bond investments for private and institutional investors.

Jupiter Asset Management Extends Relationship with SS&C

Retrieved on: 
Thursday, November 24, 2022

WINDSOR, Conn., Nov. 23, 2022 /PRNewswire/ -- SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that Jupiter Asset Management, an investment management group, has extended its transfer agency contract with SS&C. SS&C provides services to Jupiter's unit trusts and has now taken on Jupiter's OEIC fund range acquired in 2020 as part of the Merian acquisition. The entire range of funds administered by SS&C exceeds GBP28 billion.

Key Points: 
  • WINDSOR, Conn., Nov. 23, 2022 /PRNewswire/ -- SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that Jupiter Asset Management, an investment management group, has extended its transfer agency contract with SS&C.
  • Jupiter will also take advantage of SS&C's advanced data processing and analytics to gather insights into fund flow and client activity.
  • "We are pleased to extend our valued long-term relationship with Jupiter," said Nick Wright, General Manager, SS&C GIDS.
  • Jupiter Asset Managementis aU.K.fund management group, managing equity and bond investments for private and institutional investors.

NETRIS Pharma, Orano and Centre Léon Bérard Announce Scientific Collaboration to Develop Novel Antibody Radio-Conjugate Therapies

Retrieved on: 
Tuesday, September 20, 2022

NETRIS Pharma SAS, a private clinical-stage biopharmaceutical company, announced today that it has entered into a scientific collaboration agreement with Orano and the Centre Lon Brard (CLB) to develop novel Antibody Radio-Conjugates for the treatment of cancer.

Key Points: 
  • NETRIS Pharma SAS, a private clinical-stage biopharmaceutical company, announced today that it has entered into a scientific collaboration agreement with Orano and the Centre Lon Brard (CLB) to develop novel Antibody Radio-Conjugates for the treatment of cancer.
  • Initially, the parties intend to conduct a preclinical proof-of-concept efficacy study with new radio-conjugate targeting Netrin-1, combining Netris monoclonal antibody (mAb) NP137 with undisclosed radioelement from Orano.
  • Both NETRIS Pharma and Orano have entered into this collaboration with Centre Lon Brard based on the potential opportunities brought by novel radioisotope conjugates in oncology.
  • NP137, a humanized monoclonal antibody of isotype IgG1 directed against netrin-1, is the first drug candidate developed by NETRIS Pharma.